Company news

Femasys Inc. news in 2022

Femasys Inc.'s news releases, calls and decks from 2022, newest first.

View company

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

December 18, 2022

Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design

November 28, 2022

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

November 9, 2022

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

October 19, 2022

Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

October 11, 2022

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

October 5, 2022

Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team

September 28, 2022

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

August 9, 2022

Femasys Inc. Announces Existing Board Member Charles Larsen as Chairperson of the Board

July 5, 2022

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022

May 10, 2022

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2021

March 23, 2022

Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer

February 23, 2022

Femasys Inc. Announces the Appointment of Wendy Perrow, Transformational Biotech Entrepreneur, as New Board Member

January 19, 2022

Decks in 2022